ClinicalTrials.gg
RecruitingNCT07854886Updated Nov 2, 2026

Hypothalamic GLP-1 Response in Healthy Weight and Obesity

An interventional study of Gastric glucose and GLP-1(7-36)NH2 in Obesity, Normal Weight and Glucose Intolerance, sponsored by University of Copenhagen. Recruiting at 1 site in Denmark. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-02.

Sponsored by University of Copenhagen · Not applicable, Interventional, and Basic science

How we know

Updated Nov 2, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Obesity by University of Copenhagen — 5 open to participants now, 7 under way, none of them phase 3. Obesity · University of Copenhagen.

Planned enrollment
31st of 78
60 · median 50
Started
2026
with 1 other
No phase
71 of 84
5 open now
Registered
84th of 84
by date

Among the 84 studies in Obesity by University of Copenhagen, this one is the 31st largest by planned enrollment of the 78 interventional ones that give a count, is one of 2 that started in 2026, is one of 71 with no phase, and was the 84th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

5 of the 84 studies in Obesity by University of Copenhagen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Obesity by University of Copenhagen, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn how the gut hormone glucagon-like peptide-1 (GLP-1) helps the brain sense sugar. It includes adults with healthy weight and adults with obesity.

The main questions this trial aims to answer are:

A. Does GLP-1 cause the brain's response to sugar? B. Do lower GLP-1 levels cause a weaker brain response to sugar in adults with obesity?

Researchers will compare each participant's brain response across four test days. On these days, GLP-1 levels will be blocked, raised, or left unchanged. Sugar will be given either into the stomach or into a vein.

Participants will:

Attend 1 screening visit Visit the clinic for 4 test days Receive sugar and get an MRI scan of their brain on each test day

03

Conditions studied

  • Obesity
  • Normal Weight
  • Glucose Intolerance

Keywords

  • GLP-1
  • Hypothalamus
  • Obesity
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Group 1:

  • Age 18-75 years
  • 18.5-25 kg/m²
  • Normal glucose tolerance (Fasting glucose \< 5.6 mmol/L)

Group 2:

  • Age and sex-matched with group 1
  • BMI≥30 kg/m²
  • Impaired glucose tolerance (Fasting glucose 5.6 - 6.9 mmol/L)

Exclusion Criteria:

  • Diabetes mellitus type 1 or type 2, or fasting plasma glucose > 7.0 mmol/L
  • Treatment with GLP-1 receptor agonists or other GLP-1-based therapies within the past three months
  • Use of medication affecting appetite, body weight, or glucose metabolism within the past three months
  • Current eating disorder (anorexia nervosa, bulimia nervosa)
  • Known serious chronic disease, including but not limited to:

    • Heart disease
    • Anemia ( \<7.0 mmol/L for women, \<8.0 mmol/L for men)
    • Renal impairment ( \<60 mL/min/1.73m²)
    • Hepatic impairment ( or AST >3 times )
  • Known monogenic obesity
  • Substance abuse (current or within the past year)
  • Previous bariatric surgery
  • to study procedures, including:

    • Esophageal or nasal obstruction (e.g. tumors, strictures)
    • Coagulopathy
    • History of skull base trauma
    • Esophageal varices
    • Hiatal hernia
    • Claustrophobia
    • Inability to comply with MRI requirements (e.g. remaining still)
    • Presence of non-removable magnetic objects incompatible with MRI
    • Any other condition or circumstance that, in the opinion of the study physician, may compromise safe participation in the study.

Exclusion criteria for women:

  • Pregnancy, breastfeeding, or wish to become pregnant during the study period
  • Women of not using adequate
  • Women using hormonal contraception (oral contraceptives, progestin- containing implants or hormonal intrauterine device.)
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Healthy weight

    Each participant completes all four experimental conditions. Gastric glucose administration is conducted on the first test day; the following three test days are performed in randomized order.

    Other: Gastric glucose · Other: GLP-1(7-36)NH2 · Other: Exendin(9-39)NH2 · Other: Isoglycemic intravenous glucose infusion

  • Experimental
    Obesity

    Each participant completes all four experimental conditions. Gastric glucose administration is conducted on the first test day; the following three test days are performed in randomized order.

    Other: Gastric glucose · Other: GLP-1(7-36)NH2 · Other: Exendin(9-39)NH2 · Other: Isoglycemic intravenous glucose infusion

Interventions

  • OtherGastric glucose

    Gastric glucose administration with intravenous saline infusion.

  • OtherGLP-1(7-36)NH2

    GLP-1(7-36)NH2 infusion with gastric glucose administration.

  • OtherExendin(9-39)NH2

    Exendin(9-39)NH2 infusion with gastric glucose administration.

  • OtherIsoglycemic intravenous glucose infusion

    Glucose infusion with rate adjustment to replicate the individual plasma glucose excursion observed during gastric glucose administration on test day 1.

06

What researchers measure

Primary outcomes

  1. Hypothalamic response to glucose ingestion during GLP-1 receptor blockade compared with saline

    Blood oxygen level-dependent (BOLD) time series are extracted from the hypothalamus and expressed relative to the BOLD signal during fasting. The hypothalamic response to glucose ingestion is defined as the relative difference between the gastric glucose condition and the isoglycemic intravenous glucose condition, pre-specified as the net area under the curve (netAUC). This outcome is reported as the difference between conditions in each group, and compared between groups.

    Time frame: During the MRI scan on three test days

  2. Hypothalamic response to glucose ingestion during GLP-1 infusion compared with saline

    Blood oxygen level-dependent (BOLD) time series are extracted from the hypothalamus and expressed relative to the BOLD signal during fasting. The hypothalamic response to glucose ingestion is defined as the relative difference between the gastric glucose condition and the isoglycemic intravenous glucose condition, pre-specified as the net area under the curve (netAUC). This outcome is reported as the difference between conditions in each group, and compared between groups.

    Time frame: During the MRI scan on three test days

Secondary outcomes

  1. Ad libitum energy intake

    Energy intake at an ad libitum meal, recorded as an objective measure of satiety, reported as the difference between conditions within each group.

    Time frame: After the MRI scan on four test days

  2. Subjective appetite sensations

    Appetite sensations rated on visual analogue scales (0-100 mm; higher scores indicate a stronger sensation), reported as the difference between conditions within each group.

    Time frame: Immediately before and immediately after the MRI scan on four test days

  3. T2 relaxation time in the mediobasal hypothalamus

    T2 relaxation time is measured in the mediobasal hypothalamus using a T2-weighted sequence previously validated for quantification of hypothalamic gliosis. Longer T2 relaxation time indicates greater gliosis.

    Time frame: During the MRI scan on one of four test day

  4. Plasma glucose concentration

    Glucose concentration (mmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.

    Time frame: Fasting baseline and during the MRI scan on four test days

  5. Plasma GLP-1 concentration

    GLP-1 concentration (pmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.

    Time frame: Fasting baseline and during the MRI scan on four test days

  6. Plasma insulin concentration

    Insulin concentration (pmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.

    Time frame: Fasting baseline and during the MRI scan on four test days

  7. Plasma C-peptide concentration

    C-peptide concentration (pmol/L) measured in plasma at fasting baseline and at repeated time points during the MRI scan on each test day. Concentrations are reported for each group and compared between groups.

    Time frame: Fasting baseline and during the MRI scan on four test days

07

Study locations

1 of 1 sites recruiting
  • University of Copenhagen, Department of Biomedical Sciences
    Copenhagen, 2200, Denmark
    Recruiting
    • Sarah Byberg, MD, PhD · Contact
08

References and documents

Individual participant data

Plan to share: Yes — Data sharing will be in accordance with EU and General Data Protection Regulation requirements and applicable local regulations, and in accordance with trial protocol and statistical analysis plan.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Sep 2028, 23 months later.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 23 months is close to that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2026
First posted
Oct 2, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Sep 30, 2028
CompletionEst.
Sep 30, 2028
Last update
Nov 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 2, 2026
Sites
University of Copenhagen, Department of Biomedical Sciences is now Recruiting
Nov 2, 2026
Registered
First appeared on the registry
Oct 2, 2026
Show all 2 updates
  1. Nov 2, 2026
    Not yet recruiting→Recruiting
    University of Copenhagen, Department of Biomedical Sciences is now Recruiting
  2. Oct 2, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07854886
Collaborators
Copenhagen University Hospital, Rigshospitalet
Responsible party
Sarah Byberg (MD, Assistant Professor, University of Copenhagen) — Principal investigator
First posted
Oct 2, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Sep 30, 2028 (estimated)
Completion
Sep 30, 2028 (estimated)
Last update
Nov 2, 2026

Study contacts

Sarah Byberg, MD
Contact
sarah.byberg@sund.ku.dk
+45 50247452
Sarah Byberg, MD, PhD
principal investigator · University of Copenhagen, Department of Biomedical Sciences

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion